Incellipan, Injektionssuspension in Fertigspritzen

7680699410019 CH-69941 Injektionssuspension

No image available

Article details

Package size
10
Selling units
10
Measure
Fertigspritze(n)
Galenic form
Injektionssuspension
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
29/08/2026
Summary of Product Characteristics
Français
29/08/2026
Summary of Product Characteristics
Italien
29/08/2026

Detailed composition

Substance Quantity Type Category
haemagglutininum influenzae A (H5N1)
7.5 UG Substance Wirkstoff (Principe actif)
squalenum
- Substance HNIDK
polysorbatum 80
1.175 MG Substance HBESI
sorbitani trioleas
- Substance HNIDK
natrii citras dihydricus
- Substance HNIDK
acidum citricum
- Substance HNIDK
natrii chloridum
- Substance HNIDK
kalii chloridum
- Substance HNIDK
kalii dihydrogenophosphas
- Substance HNIDK
dinatrii phosphas dihydricus
- Substance HNIDK
magnesii chloridum hexahydricum
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
1.88 MG Substance HBESI
kalium
0.102 MG Substance HBESI

Authorization holder

Vifor (International) Inc.

9014 St. Gallen

Authorization information

Swissmedic authorization number
69941
Drug name
Incellipan, Injektionssuspension in Fertigspritzen
Galenic form
INJFS
ATC Code
J07BB02
Authorization status
Z
Dispensing category
B
First authorization
25/06/2026
Authorization expiration date
24/06/2031
IT Number
08.08.
Domain
Human medicine
Field of application
Aktive Immunisierung von Erwachsenen und Kindern ab 6 Monaten gegen Influenza bei einer offiziell ausgerufenen Pandemie

Package details

Description (FR)
INCELLIPAN sol inj 7.5 µg 0.5 ml PFS 10 pce
Description (DE)
INCELLIPAN Inj Lös 7.5 µg 0.5 ml PFS 10 Stk
Market launch
01/06/2029
Narcotic (BTM)
No
Buy us a coffee Explore the data